About CareDX
Founded in 1998, CareDx specialises in molecular diagnostics and precision medicine technologies for transplant medicine, with additional capabilities in cell therapy and specialty oncology. The company develops non-invasive approaches for monitoring organ health, graft function and rejection risk, enabling clinicians and researchers to assess transplant status using genomic and molecular biomarkers rather than relying solely on invasive biopsy procedures. Its expertise combines molecular testing, bioinformatics and clinical evidence generation to support decision-making throughout the transplant pathway, including pre-transplant assessment, post-transplant surveillance and long-term graft monitoring.
CareDx’s portfolio includes the AlloSure® donor-derived cell-free DNA (dd-cfDNA) testing platform for kidney, heart and lung transplant monitoring, the AlloMap® gene expression profiling assay for heart transplant rejection surveillance, and HeartCare®, which integrates multiple molecular measures to provide a more comprehensive assessment of transplant health. The company also offers digital workflow technologies and data-driven tools that support transplant centres in managing patient monitoring and clinical workflows. These solutions are used in transplantation research and clinical programmes focused on early detection of allograft injury, rejection monitoring and long-term graft preservation.
Europa Biosite’s subsidiaries distribute for CareDX in Austria, Belgium, Luxembourg and the Netherlands.